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Abstract 
Background:  Primary open angle glaucoma is a heterogeneous group of optic neuropathies that results in optic 
nerve degeneration and a loss of retinal ganglion cells (RGCs) ultimately causing blindness if allowed to progress. Eleva-
tion of intraocular pressure (IOP) is the most attributable risk factor for developing glaucoma and lowering of IOP is 
currently the only available therapy. However, despite lowering IOP, neurodegenerative effects persist in some patients. 
Hence, it would be beneficial to develop approaches to promote neuroprotection of RGCs in addition to IOP lower-
ing therapies. The endothelin system is a key target for intervention against glaucomatous neurodegeneration. The 
endothelin family of peptides and receptors, particularly endothelin-1 (ET-1) and endothelin B (ETB) receptor, has been 
shown to have neurodegenerative roles in glaucoma. The purpose of this study was to examine changes in endothelin 
A (ETA) receptor protein expression in the retinas of adult male Brown Norway rats following IOP elevation by the Mor-
rison’s model of ocular hypertension and the impact of ETA receptor overexpression on RGC viability in vitro.
Results: IOP elevation was carried out in one eye of Brown Norway rats by injection of hypertonic saline through 
episcleral veins. After 2 weeks of IOP elevation, immunohistochemical analysis of retinal sections from rat eyes showed 
an increasing trend in immunostaining for ETA receptors in multiple retinal layers including the inner plexiform layer, 
ganglion cell layer and outer plexiform layer. Following 4 weeks of IOP elevation, a significant increase in immu-
nostaining for ETA receptor expression was found in the retina, primarily in the inner plexiform layer and ganglion 
cells. A modest increase in staining for ETA receptors was also found in the outer plexiform layer in the retina of rats 
with IOP elevation. Cell culture studies showed that overexpression of ETA receptors in 661W cells as well as primary 
RGCs decreases cell viability, compared to empty vector transfected cells. Adeno-associated virus mediated overex-
pression of the ETA receptor produced an increase in the ETB receptor in primary RGCs.
Conclusions: Elevated IOP results in an appreciable change in ETA receptor expression in the retina. Overexpression 
of the ETA receptor results in an overall decrease in cell viability, accompanied by an increase in ETB receptor levels, 
suggesting the involvement of both ETA and ETB receptors in mediating cell death. These findings raise possibilities for 
the development of ETA/ETB dual receptor antagonists as neuroprotective treatments for glaucomatous neuropathy.
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Background
Glaucoma is a common optic neuropathy character-
ized by dysfunction and degeneration of retinal ganglion 
cell (RGC) axons, optic nerve head cupping, and loss of 
RGCs, ultimately resulting in irreversible vision loss. Pri-
mary open angle glaucoma (POAG) is one of the most 
common types of glaucoma and is a slowly developing 
neurodegenerative disease. Progressing without pain or 
overt symptoms, POAG can cause significant neuro-
degeneration of RGCs and their axons before any visual 
deficits are discernible. More than 2 million Americans 
and approximately 60 million people worldwide are cur-
rently affected by glaucoma and based on statistical esti-
mates that number is expected to reach 3 million patients 
in America and almost 80 million worldwide by the year 
2020 [1]. Risk factors for developing glaucoma include age 
(over 60 years), myopia and race, with African-Americans 
being much more likely to develop POAG than Cau-
casians [2]. From the point of view of therapy, the most 
readily detectable and treatable risk factor for POAG is an 
elevation in intraocular pressure (IOP). Currently surgical 
and pharmacological treatments for POAG are primarily 
aimed at lowering IOP which have been shown to delay 
the progression of POAG. Since it is possible to develop 
glaucomatous neuropathy without an increase in IOP and 
given that in some patients POAG may still progress after 
treatment, it is important to identify other possible etio-
logical contributors and treatment options for POAG.
One key contributor to the progression of glaucomatous 
optic  neuropathy is the endothelin system of vasoactive 
peptides. Endothelins belong to a family of potent vasoac-
tive peptides comprising of three isoforms: endothelin-1 
(ET-1), endothelin-2 (ET-2), and endothelin-3 (ET-3) [3, 
4]. The peptides act through two classes of G-protein cou-
pled receptors: endothelin receptor A (ETA) and endothe-
lin receptor B (ETB). Endothelins and their receptors have 
been shown to be present in multiple ocular tissues includ-
ing the ciliary body, trabecular meshwork (TM) [5], retina 
[6, 7], and lamina cribrosa [8].
Previous reports have shown that ET-1 levels are ele-
vated in human patients with primary open angle glau-
coma [9–11], as well as in the congenital beagle model 
of glaucoma [12]. Endothelins have also been found to 
be elevated in the aqueous humor in the Morrison’s 
model of glaucoma [13] as well as in retinal microglia in 
the DBA/2J inherited model of glaucoma [14]. Although 
endothelin levels are shown to be elevated during glau-
coma, direct evidence for the contribution of endothelin 
to glaucomatous neurodegeneration can be best assessed 
using animal models of glaucoma. Studies have shown 
that administration of ET-1 can produce degeneration 
of RGC axons in multiple animal models [15–19] and 
induce apoptosis of RGCs in rats [20].
A recent study in a mouse model showed activation of 
the endothelin system occurs early in glaucoma develop-
ment before any observed morphological changes [14]. 
Administration of bosentan, a dual endothelin receptor 
antagonist (that blocks both ETA and ETB receptors) in 
the diet (100 mg/kg), was found to promote neuroprotec-
tion [14]. Previous studies from our laboratory demon-
strated that following ocular hypertension, rats deficient 
in ETB receptors showed a significant reduction in RGC 
loss compared to that seen in wild type rats [21]. How-
ever, the status of ETA receptors under conditions of 
ocular hypertension and their precise role in neurode-
generation is not completely understood. The current 
study was aimed at understanding changes in ETA recep-
tor expression in the retinas of rats with elevated IOP.
Methods
Induction of ocular hypertension in adult Brown Norway 
rats
All animal procedures were carried out in accordance with 
the ARVO resolution for the Use of Animals in Ophthal-
mic and Vision Research. The protocol was approved by the 
Institutional Animal Care and Use Committee (IACUC) at 
the University of North Texas Health Science Center. For 
the current study, the Morrison’s model was used to induce 
ocular hypertension in adult male retired breeder Brown 
Norway rats as previously described [22]. Briefly, intraocular 
pressure was raised in one eye (by injecting approximately 
50 µL of hypertonic saline through episcleral veins), while the 
other eye served as the contralateral control. Animals were 
sedated by intraperitoneal injection (100 µL/100 g body wt) 
of an anesthesia cocktail containing 55.6 mg/mL Ketamine 
(VEDCO), 5.6 mg/mL Xylazine (VEDCO), and 11.1 mg/mL 
Acepromazine (Lloyd Laboratories). After sedating the ani-
mals a small incision was made in the conjunctiva to expose 
the episcleral veins. A 1.8 M NaCl solution was then injected 
into an episcleral vein using a glass needle (TIP01TW1F, 
WPI) at a rate of 309 µL/min for 10 s. IOP was measured 2–3 
times a week using a TonoLab tonometer (iCare, Finland). 
Six pressure readings were averaged for each IOP measure-
ment and ten IOP measurements were obtained for each eye. 
IOP plots were generated from IOP values obtained from the 
surgically treated eye and contralateral control eye. The IOP 
exposure in each rat was computed by the integral product 
of the extent of IOP elevation and the number of days for 
which it maintained (expressed as mmHg-days).  Typically, 
we get IOP exposures of approximately 61 to 90 mm Hg-
days for 2 weeks of IOP elevation and 98 to 140 mm Hg-days 
for 4 weeks of IOP elevation.
Immunohistochemistry
Animals were sacrificed by intraperitoneal  pentobar-
bital injection  (120 mg/kg body wt)  and then eyes were 
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carefully enucleated. A small incision (approximately 
4–5 mm) was made using an ophthalmic micro surgical 
knife (MVR 20G, 160710, Cambrian-Medical) just poste-
rior to the limbus and the eye was fixed in 4% PFA for 
30  min. After fixation for 30  min the incision was con-
tinued around the eye until the entire anterior segment, 
including the lens, was completely removed. The poste-
rior segment was fixed in 4% PFA for an additional 2.5 h. 
Eyes were then washed and placed in 70% ethanol until 
paraffin embedding. Sagittal retinal sections through the 
optic nerve (10  μm) were obtained using a microtome. 
Following deparaffinization, sections were blocked for 
1  h in 5% normal donkey serum containing 5% BSA in 
PBS at room temperature. Sections were incubated in 
primary antibody and subsequently incubated with the 
appropriate secondary antibodies for 1  h each at room 
temperature. To detect any background staining, blank 
sections were prepared using the same protocol; how-
ever no primary antibody was added (Additional file  1: 
Figure S1, Additional file 2: Figure S2). Primary antibod-
ies used were rabbit anti-ETA (1:100, Sigma) and mouse 
anti-β-III-tubulin (1:500, Sigma). Secondary antibodies 
used were donkey anti-rabbit Alexa 647 (1:1000, Invit-
rogen) and donkey anti-mouse Alexa 488 (1:1000, Inv-
itrogen). Sections were mounted and kept in Prolong® 
Gold antifade reagent with DAPI (P36931, Invitrogen). 
Images were taken using a Zeiss LSM 510 META confo-
cal microscope.
Relative fluorescence intensity (RFI) measurements
Retina sections
An integrated projection of confocal z-stacks was cre-
ated for every image and the fluorescence intensity was 
measured using ImageJ software. The freehand region 
of interest (ROI) tool was used to outline the regions of 
the retina to be analyzed. Bright field images were used 
for selecting ROIs. Once selected, ROIs were added to 
the ROI manager and overlaid onto the red channel (ETA 
antibody) before measuring intensity. Values obtained 
for blank sections (no primary antibody) were averaged 
and served as background which was subtracted from 
the experimental values. After the background was sub-
tracted, the measurements for each eye were averaged to 
obtain the mean fluorescence intensity. For each animal, 
the fluorescence intensity from contralateral (control) 
eyes were set to 1 to determine the relative change in ETA 
receptor expression between IOP elevated and contralat-
eral eyes.
Retinal ganglion cells
To measure expression of ETA and ETB receptors in pri-
mary RGCs confocal z-stack projections were gener-
ated for each image. The bright field images were used 
to visualize cells and the freehand ROI tool was used to 
trace somas which showed co-staining for β-III-tubulin 
(red fluorescence). Each trace was added to the ROI man-
ager and overlaid onto the pink channel (ETA and ETB 
receptors) before measuring fluorescence intensity.
661W cell transfection and culture
For most cell culture experiments, transformed 661W 
photoreceptor cells were used. The 661W cells were 
grown in DMEM/low glucose media (Thermo Scien-
tific) containing 10% fetal bovine serum (F2442, Sigma), 
100 units/mL penicillin and 100  µg/mL streptomycin 
(SV30010, GE Healthcare). Stable clones overexpress-
ing the ETA receptor were generated by transfecting 
661W cells with an ETA receptor cDNA plasmid con-
struct using Lipofectamine 2000 (11668-019, Invitrogen) 
and applying selection pressure with Geneticin (G418, 
300  µg/mL) for 4  weeks. Briefly, cells were transfected 
with either pCMV6-Empty vector or pCMV6-ETA 
expression vector (Origene, Rockville, MD) in DMEM 
serum-free media for 24  h and then placed in DMEM 
complete media for 24 h. Cells were dissociated by incu-
bation in 0.0625% trypsin for 5 min at 37 °C and diluted 
to yield approximately 20  cells/mL and 100  µL of the 
cell suspension was added to multiple wells of a 96-well 
plate. Cells were then allowed to grow in DMEM com-
plete media containing Geneticin (300 µg/mL) and were 
maintained for 4 weeks. Individual clones of 661W cells 
that displayed resistance to Geneticin were isolated, 
plated into separate wells of a 24-well plate and propa-
gated further. Four stable clones were generated for both 
pCMV6-Empty and pCMV6-ETA receptor expression 
vectors. ETA receptor expression was confirmed by west-
ern blot and the clone yielding the highest level of ETA 
receptor expression was used for further experiments.
Live/dead assay
Stable clones of 661W cells expressing either empty vector 
or the ETA receptor were counted using a hemocytometer 
and seeded in 24-well plates and grown to 50–60% conflu-
ence. Clones were treated with either DMEM serum-free 
media or DMEM serum-free media containing 100  nM 
ET-1 or ET-3 and allowed to incubate at 37  °C for 24 h. 
Following incubation, cells were washed twice using Dul-
becco’s Phosphate Buffered Saline (DPBS) (#14278072, 
Gibco) and incubated with a Live/Dead assay kit (L3224, 
Life Technologies) for 30  min. Living cells were labeled 
green with Calcein AM and dead/dying cells were labeled 
red by Ethidium homodimer (EthD-1). Cell nuclei were 
labeled with a Hoechst stain to observe and obtain total 
cell numbers. Images were taken using a fluorescent 
microscope and cell counts were performed using ImageJ 
software (NIH, http://imagej.nih.gov/ij).
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MTT assay
MTT assays were performed using 661W cells stably 
overexpressing either the empty plasmid vector or ETA 
cDNA encoding plasmid. A hemocytometer was used to 
count the cells and approximately 2000 cells were seeded 
in a black-wall clear-bottom 96 well plate. The cells were 
allowed to grow overnight at 37  °C. Before treatment, 
cells were washed once in DMEM serum-free media. 
Empty vector and ETA vector expressing cells were then 
treated with 100 nM ET-1 or 100 nM ET-3 for 24 h. Fol-
lowing treatment, cells were washed once with DMEM 
serum-free media and then 20 μL of Promega CellTiter96 
Aqueous One Solution was added to each well. The plate 
was incubated for 30  min and then the absorbance was 
measured at 490  nm for each well. Readings were taken 
using the Cytation5 (Bio-Tek). A standard curve was gen-
erated by measuring absorbance readings for wells seeded 
with 2000, 4000 and 8000 cells  (Additional file  3: Figure 
S3). The standard curve was then used to extrapolate cell 
numbers from experimental absorbance readings.
Fluorescence Assisted Cell Sorting (FACS) analysis
Stable clones overexpressing either the empty vector or 
the ETA plasmid vector were used to assess differences in 
cell cycle by flow cytometry. Approximately 200,000 cells 
were seeded for each 100  mm dish for both Empty and 
ETA expression vectors. Cells were allowed to reach 60% 
confluence and were treated with either  100  nM ET-1 
or 100  nM ET-3 for 24  h in DMEM serum-free media. 
Untreated cells were also kept in DMEM serum-free 
media for 24 h. Following treatment, media was removed 
to collect any floating cells and spun down. Adherent 
cells were removed via trypsinization (0.0625%) for 5 min 
and spun down. The floating and adherent cell pellets 
were resuspended in 100  μL and 1  mL of PBS, respec-
tively, and then combined. After adding the suspensions 
together 3.3  mL Ethanol was added to the cell suspen-
sion, mixed well, and stored overnight at −20  °C. The 
cells were spun down, resuspended in 500  μL PBS, and 
a cell count was performed. Approximately 500,000 cells 
were transferred to a flow cytometry tube (352058, BD 
Falcon) and the volume was made up to 500 μL with PBS. 
Cells were incubated with 2.5 μL of RNase A (20 mg/mL) 
for 30 min at 37 °C followed by 5 μL of propidium iodide 
(1  mg/mL) for 30  min at room temp. Cell cycle analy-
sis was conducted using a Beckman Coulter Cytomics 
FC500 Flow Cytometry Analyzer.
Western blot analysis
Stable clones overexpressing either the empty vector 
or the ETA receptor plasmid vector were grown to con-
fluence on 100 mm dishes. Cells were harvested using 
ice cold PBS and spun down at 3300 rpm for 5 min at 
4  °C. Pellets were resuspended in an isotonic buffer 
(20 mM HEPES; 1 mM EDTA; 0.25 M sucrose; 0.5 mM 
PMSF, 1 mM DTT; 1× Halt protease inhibitor (78430, 
Thermo Scientific); 100 mM NaF; 1 mM Na3VO4. Cells 
were lysed by sonication and spun down at 12,000×g 
for 5  min at 4  °C. The supernatant was collected and 
spun down at 100,000×g for 45 min at 4 °C. The result-
ing pellet was then resuspended using an isotonic 
detergent buffer (20 mM HEPES; 1 mM EDTA; 0.25 M 
sucrose; 0.5 mM PMSF; 1 mM DTT; 1× Halt protease 
inhibitor; 0.1% Igepal CA 630; 0.1% Triton-X-100). Pro-
tein concentration was determined using spectropho-
tometry and 10–20 μg of protein was used for western 
blot experiments. Primary antibodies used to probe 
blots were rabbit anti-ETA (1:1000; Sigma), rabbit anti-
ETB (1:10,000, Antibody Research Corporation), rab-
bit anti-Calnexin (1:1000, Cell Signaling) and mouse 
calnexin (1:1000, Cell Signaling). Secondary antibod-
ies used were donkey anti-Rabbit HRP (1:10,000, GE 
Healthcare) and sheep anti-Mouse HRP (1:10,000, GE 
Healthcare). Blots were developed using SuperSig-
nal™ West Dura extended duration substrate (34,075, 
Thermo Scientific).
Adeno‑associated virus production
Adeno-associated virus serotype 2 (AAV-2) encoding 
the ETA receptor was generated in the lab by inserting 
ETA cDNA (OriGene) into the AAV-2-IRES-hrGFP vec-
tor (Agilent Technologies, Santa Clara, CA). The restric-
tion enzymes SalI-HF (New England Biolabs, Ipswich, 
MA) and XhoI (Promega, Madison, WI) were used to 
clone the ETA cDNA fragment into the AAV-2-IRES-
hrGFP vector. The resulting AAV-2-ETA plasmid was 
sequenced (Lone Star Labs) to confirm the nucleotide 
sequence and ensure the cDNA was properly oriented. 
The AAV-2-IRES-hrGFP vector was used as control. The 
AAV-2-ETA virus and AAV-2-GFP (control) viruses were 
then generated using AAV Helper-Free System accord-
ing to the manufacturer’s protocol. Viral titer was deter-
mined using QuickTiter™ AAV Quantitation Kit (Cell 
Biolabs, Inc).
Isolation and AAV‑2 transduction of primary RGCs
Retinal ganglion cells were isolated and purified as pre-
viously described [23]. Briefly, RGCs were obtained from 
post-natal day 5 Sprague Dawley rat pups and purified by 
immunopanning. RGCs were positively selected for using 
the Thy1.1 antibody. Cells were seeded and grown in a 
96-well plate (5000 cells/well) or 12-mm glass coverslips 
(30,000 cells/coverslip) and incubated in 10% CO2. RGCs 
were allowed to attach and produce neurites for 7  days 
prior to further experiments. The growth medium was 
changed every 3 days throughout the experiment.
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Immunocytochemistry
Primary RGCs were seeded and grown on 12-mm glass 
coverslips. Seven days after seeding, AAV-2-GFP and 
AAV-2-ETA was added to the cells and viral transduc-
tion was allowed to proceed for 11 days to permit robust 
expression of ETA receptors. The growth medium was 
removed and cells were fixed using 4% PFA. After fixa-
tion, a permeablization buffer (0.1% sodium citrate, 
0.1% Triton-X-100 in PBS) was added to each well for 
5 min. Cells were incubated in blocking buffer (5% nor-
mal donkey serum, 5% bovine serum albumin in PBS) 
for 1  h at room temperature. Primary antibodies were 
diluted in antibody dilution buffer (1% BSA in PBS) and 
RGCs were incubated overnight at 4  °C. Primary anti-
bodies used were rabbit anti-ETA (1:100, Sigma), rabbit 
anti-ETB (1:500 Antibody Research Company), mouse 
anti-β-III-tubulin (1:500, Sigma). Secondary antibodies 
were diluted in antibody dilution buffer and cells were 
incubated for 1 h at room temperature. Secondary anti-
bodies used were donkey anti-rabbit Alexa 546 and don-
key anti-mouse Alexa 647. Coverslips were mounted on 
slides using Prolong® Gold antifade reagent with DAPI 
(P36931, Invitrogen). Images were taken with the Zeiss 
510 Meta confocal microscope.
Results
Immunostaining for the ETA receptor is increased in the 
retina of Brown Norway rats with elevated IOP
Our laboratory has previously demonstrated that the 
endothelin receptor B (ETB) is upregulated following an 
increase in IOP and contributes to the degeneration of 
RGCs [21]. The focus of the present study was to deter-
mine if similar changes in the ETA receptor expression 
was observed after IOP elevation. Following 2  weeks of 
IOP elevation in Brown Norway rats, retinas obtained 
from both IOP elevated and contralateral control eyes 
showed immunoreactivity for ETA receptors in multiple 
retinal layers including the nerve fiber layer (NFL), gan-
glion cell layer (GCL), inner plexiform layer (IPL), and 
outer plexiform layer (OPL) (Fig.  1b). Compared to the 
contralateral controls, a qualitative analysis of retinas 
obtained from IOP elevated eyes showed an increasing 
trend in ETA receptor expression within the OPL, IPL 
and GCL. Expression of ETA receptors was colocalized 
with RGCs using β-III-tubulin which is a selective neu-
ronal marker (Fig.  1b). Additionally, a modest increase 
in immunostaining for ETA receptors was also observed 
in the NFL compared to the contralateral controls. A 
semi-quantitative analysis measuring the change in flu-
orescence intensity was also performed using ImageJ 
software. Projections from confocal image z-stacks were 
analyzed for relative fluorescence intensity of ETA recep-
tor expression in IOP elevated eyes and corresponding 
contralateral control eyes to determine fold change. 
While five out seven rats showed an increase in immu-
nostaining for the ETA receptors, two of the seven rats 
showed a slight decrease, thereby did not attain statisti-
cal significance at the 2  week time point of IOP eleva-
tion (retina, RFI = 1.57 ± 0.34; OPL, RFI = 1.40 ± 0.28; 
IPL, RFI =  1.51 ±  0.33; GCs, RFI =  2.40 ±  0.98; NFL, 
RFI  =  1.54  ±  0.46), however there was a clear trend 
towards an increase in immunostaining for ETA recep-
tors (Fig. 1c).
Similar to the pattern of expression observed at 
2  weeks of IOP elevation, increased immunoreactivity 
for ETA receptor in the retina was also observed in the 
NFL, GCL, IPL, and OPL (Fig. 2b). Retinas obtained from 
Brown Norway rats following 4  weeks of IOP elevation 
qualitatively showed the greatest increase in immuno-
reactivity for ETA receptors in the IPL and GCL. A faint 
increase in ETA receptor expression was also observed 
in the NFL and OPL. A semi-quantitative analysis was 
performed which indicated a statistically significant 
increase in ETA receptor expression overall in the ret-
ina (RFI =  1.37 ±  0.04, n =  4, p  <  0.001) as well as in 
the IPL (RFI  =  1.35  ±  0.14, n  =  4, p  <  0.05) and GCs 
(RFI =  1.59 ±  0.16, n =  4, p  <  0.01) following 4  weeks 
of IOP elevation (Fig. 2c). Statistical significance was not 
reached in either the OPL (RFI = 1.43 ± 0.23) or the NFL 
(RFI = 1.38 ± 0.30) however the same trend of increased 
ETA receptor expression was still present. Taken together, 
the data suggest that ETA receptor expression was upreg-
ulated due to ocular hypertension in rats and that the 
increase in ETA receptor expression was sustained during 
longer durations of IOP elevation.
Stable overexpression of the ETA receptor produces an 
increase cell death in 661W cells
In order to elucidate the role of ETA receptor in the retina 
and its possible contribution to neurodegeneration, stable 
clones were generated by transfecting 661W photorecep-
tor cells with either an ETA receptor cDNA vector or the 
corresponding empty plasmid vector. A live/dead assay 
using Calcein AM and Ethidium homodimer-1 (EthD-1) 
was performed with the stable ETA receptor clone and 
the empty vector clone following a 24 h treatment with 
either 100 nM ET-1 or ET-3. Cells were also labeled using 
Hoechst nuclear stain for visualization and quantita-
tion of total cell numbers (Fig. 3a). Analysis of EthD-1+ 
cells (dead/dying cells, red fluorescence) in empty vec-
tor transfected group revealed no change in the percent-
age of dead/dying cells following treatment with either 
100 nM ET-1 (1.22 ± 0.15%) or ET-3 (1.33 ± 0.17%) com-
pared to untreated cells (1.44 ±  0.25%) (Fig.  3b). Stable 
clones overexpressing the ETA receptor, regardless of 
treatment group, showed an increase in the percentage 
Page 6 of 16McGrady et al. BMC Neurosci  (2017) 18:27 
Fig. 1 ETA expression in retinas of adult Brown Norway rats following 2 week IOP elevation. a Representative graph of IOP measurements for IOP 
elevated (white circles) and contralateral control (black circles) eyes in adult male Brown Norway rats. b Representative images. Immunostaining of 
retina sections probed for ETA receptors (red fluorescence) and β-III-tubulin (green fluorescence) following 2 weeks of IOP elevation. Arrows point to 
RGCs. c Relative fluorescent intensity for the retina, OPL, IPL, GCs and NFL. Bars represent mean ± SEM (n = 7 animals/group). ONL outer nuclear 
layer, OPL outer plexiform layer, INL inner nuclear layer, IPL inner plexiform layer, GCL ganglion cell layer, NFL nerve fiber layer, TubIII β-III-tubulin
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Fig. 2 ETA expression in retinas of adult Brown Norway rats following 4 week IOP elevation. a Representative graph of IOP measurements for IOP 
elevated (white circles) and contralateral control (black circles) eyes in adult male Brown Norway rats. b Representative images. Immunostaining 
of retina sections probed for ETA receptors (red fluorescence) and β-III-tubulin (green fluorescence) following 4 weeks of IOP elevation. Arrows point 
to RGCs. c Relative fluorescent intensity for the retina, OPL, IPL, GCs and NFL. Bars represent mean ± SEM (n = 4 animals/group). Asterisks indicate 
statistical significance *p < 0.05; **p < 0.01; ***p < 0.001 by student’s t-test. ONL outer nuclear layer, OPL outer plexiform layer, INL inner nuclear layer, 
IPL inner plexiform layer, GCL ganglion cell layer, NFL nerve fiber layer, TubIII β-III-tubulin
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of dead/dying cells when compared to empty vector 
clones. There was no further exacerbation of cell death 
in ETA vector expressing cells (2.28 ±  0.22%) following 
treatment of either 100 nM ET-1 (2.39 ± 0.23%) or ET-3 
(2.30 ± 0.24%) (Fig. 3b).
In addition to quantifying the percentage of dead/dying 
cells, Calcein AM+ cells (living, green fluorescence) were 
also analyzed. No decrease in the percentage of living 
cells was observed in empty vector cells (98.77 ± 0.18%) 
following 24  h treatment with either 100  nM ET-1 
(98.03 ± 0.21%) or 100 nM ET-3 (97.85 ± 0.21%) (Fig. 3c). 
The percentage of living ETA receptor overexpressing 
cells (98.33  ±  0.22%) was reduced after treatment with 
ET-1 (97.37 ± 0.21%, n = 3, p < 0.05) but not with ET-3 
(97.69 ± 0.24%) (Fig. 3c). Using Hoechst staining to quan-
tify total cells in each treatment group, we consistently 
found a lesser number of total cells in wells containing 
ETA overexpressing cells (811.89  ±  48.56) compared 
to empty vector cells (1013.94  ±  72.91) (Fig.  3d). Total 
cell number was further reduced in empty vector cells 
after treatment with either ET-1 (639.83 ± 48.75, n = 3, 
p < 0.001) or ET-3 (655.12 ± 76.45, n = 3, p < 0.001). Cell 
numbers for the ETA vector transfected group were fur-
ther decreased following ET-1 treatment (613.42 ± 60.37) 
and reached statistical significance in the ET-3 treatment 
group (508.94 ± 52.50, n = 3, p < 0.01) (Fig. 3d).
ETA receptor overexpression in 661W cells results 
in decreased cell viability
To clarify the above findings, an additional cell viabil-
ity/proliferation assay was performed. To confirm that 
ETA overexpression compromises cell viability, an MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) cell proliferation assay was performed on 
Fig. 3  Live-Dead assay of 661W cells stably overexpressing the ETA receptor. a Representative images of EthD-1 (red fluorescence), calcein AM 
(green fluorescence) and Hoechst (blue fluorescence) labeled 661W stable clones indicating dead, living and total cells respectively. Images were taken 
following 24 h treatment with either 100 nM ET-1 or ET-3. b–d Quantitative analysis of b EthD-1+, c calcein AM+ and d Hoechst labeled cells. Bars 
represent mean ± SEM (n = 3). Asterisks indicated statistical significance *p < 0.05; **p < 0.01; ***p<0.001 by one-way ANOVA and Tukey’s post hoc 
test
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empty vector and ETA cDNA overexpressing 661W 
cells. Absorbance readings at 490  nm were taken for 
each well of a 96-well plate. Empty vector transfected 
cells treated with 100  nM ET-1 (Abs  =  0.310  ±  0.014) 
or 100 nM ET-3 (Abs = 0.289 ± 0.023) for 24 h showed 
a decreasing trend in absorbance readings compared 
to untreated empty vector cells (Abs  =  0.328  ±  0.019) 
though not statistically significant (Fig.  4a). Absorb-
ance readings for cells overexpressing the ETA receptor 
(Abs = 0.289 ± 0.015) did not show a significant decrease 
compared to empty vector cells. The greatest reduction 
in absorbance was observed in ETA vector cells treated 
with 100 nM ET-3 (Abs = 0.235 ± 0.020) for 24 h, how-
ever, no change was detected after treatment with ET-1 
(Abs =  0.298 ±  0.013), compared to the untreated ETA 
receptor transfected cells (Fig. 4a). A standard curve gen-
erated from absorbance readings from known cell num-
bers was used to extrapolate the number of cells in the 
experimental groups (Fig. 4b).
These results are in line with the live/dead assay and 
which shows a decrease in cell viability for cells overex-
pressing the ETA receptor. Interestingly in both assays, 
the increase in cell death was most prominent following 
treatment with ET-3, an ETB receptor agonist.
Cell cycle kinetics is altered by stable overexpression of the 
ETA receptor in 661W cells
After demonstrating that ETA receptor overexpression 
affected cell viability in the 661W stable clone, we wanted 
to further explore the effect of ETA receptor overexpres-
sion on the cell cycle. Fluorescence-Assisted Cell Sorting 
(FACS) analysis using propidium iodide (PI) was utilized 
to observe if there were alterations in certain phases of 
the cell cycle between empty vector and ETA receptor 
overexpressing cells.
Analysis of the histogram plots revealed differences in 
the G0/G1 phase peak (arrowheads) and the Sub G phase 
peak (arrows) between empty vector and ETA recep-
tor vector cells (Fig. 5a). No difference was found in the 
G2M and S phases for empty or ETA receptor vector 
cells (Fig.  5b). There was no change in the G0/G1 peak 
for empty vector cells after treatment with either 100 nM 
ET-1 or ET-3 (empty: 61.96  ±  2.04%; empty ET-1: 
64.23  ±  1.27%; empty ET-3: 63.41  ±  1.46%) or in ETA 
vector cells following treatment (ETA: 55.90 ± 0.62%; ETA 
ET-1: 55.12 ± 1.52%; ETA ET-3: 56.75 ± 2.27%) (Fig. 5c). 
Statistical significance was reached in G0/G1 phase 
between empty vector ET-1 treated cells versus ETA vec-
tor ET-1 treated cells (64.23  ±  1.27 vs. 55.12  ±  1.52%, 
n  =  3, p  <  0.05) and empty vector ET-1 treated cells 
versus ETA vector cells (64.23 ± 1.27 vs. 56.75 ± 2.27%, 
n = 3, p < 0.05). A significant difference was also seen in 
empty vector ET-3 treated cells versus ETA vector ET-1 
treated cells (63.41  ±  1.46 vs. 55.12  ±  1.52%, n  =  3, 
p < 0.05) (Fig. 5c).
Assessment of the Sub G peak also showed no dif-
ference between empty vector cells following ET-1 or 
ET-3 treatment (empty: 4.96  ±  0.57%; empty ET-1: 
4.11 ± 0.93%; empty ET-3: 5.07 ± 0.84%) or between ETA 
vector cells following treatment (ETA: 10.20  ±  1.42%; 
ETA ET-1: 11.09  ±  1.23%; ETA ET-3: 9.47  ±  1.46%) 
(Fig.  5d). There was a trend towards an increase of the 
SubG peak in ETA vector cells compared to empty vec-
tor cells although it did not reach statistical significance 
(10.20 ± 1.42 vs. 4.96 ± 0.57%, n = 3). Significance was 
reached however between ETA vector ET-1 treated cells 
and empty vector cells (11.09  ±  1.23 vs. 4.96  ±  0.57%, 
Fig. 4 ETA receptor overexpression reduces overall cell viability in 
661W cells. a Quantitative analysis of MTT assay absorbance readings 
at 490 nm for empty vector and ETA receptor vector stable clones 
following 24 h treatment with either 100 nM ET-1 or ET-3. b Graph 
of interpolated cell counts generated from a standard curve and 
experimental absorbance readings. Bars represent mean ± SEM 
(n = 20). Asterisks indicated statistical significance *p < 0.05 by one-
way ANOVA and Tukey’s post hoc test
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n  =  3, p  <  0.05). A difference was also observed 
between empty vector ET-1 treated cells and ETA vec-
tor cells (4.11 ± 0.93 vs. 10.20 ± 1.42%, n = 3, p < 0.05) 
as well as ETA vector ET-1 treated cells (4.11 ± 0.93 vs. 
11.09 ± 1.23%, n = 3, p < 0.05). Empty vector cells treated 
with ET-3 also showed a significant difference from ETA 
vector ET-1 treated cells (5.07 ± 0.84 vs. 11.09 ± 1.23%, 
n = 3, p < 0.05) (Fig. 5d).
Overexpression of ETA receptors upregulate ETB receptor 
expression in 661W cells
Considering that the ET-3 peptide is selective for the ETB 
receptor and has low affinity for the ETA receptor it was 
interesting to see decreased cell viability in ETA recep-
tor overexpressing cells treated with ET-3 (Figs. 3, 4). To 
explain how ETA receptor overexpressing cells treated 
with the ET-3 peptide showed a reduction in total cell 
Fig. 5 ETA receptor overexpression alters cell cycle in 661W cells. a Representative images. FACS analysis of cell cycle in empty and ETA receptor 
vector 661W stable clones following 24 h treatment with either 100 nM ET-1 or ET-3. Arrows show Sub G peak; arrowheads show G0/G1 peak. b–d 
Quantitation of b cell cycle phases, c G0/G1 phase and d Sub G phase. Bars represent mean ± SEM (n = 3). Asterisks indicated statistical significance 
*p < 0.05, by one-way ANOVA and Tukey’s post hoc test. ns no statistical significance
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numbers in both the live/dead assay and the MTT assay, 
we wanted to know if there were changes in the expres-
sion of ETB receptors. To determine this, we performed 
an immunoblot analysis to determine changes in ETB 
receptor expression in cells overexpressing ETA recep-
tors. ETB receptor expression was found to be variable in 
cells overexpressing the ETA receptor. In some samples 
ETB expression was relatively unchanged while in other 
samples there was an almost twofold increase in expres-
sion. Overall, there was an increasing trend in ETB recep-
tor levels in 661W cells stably overexpressing the ETA 
receptor (Fig. 6).
ETA receptor overexpression increases cell death 
in primary RGCs
Since the above data was collected from the 661W cell 
line, we wanted to determine if ETA receptor overexpres-
sion showed the same increase in cell death of primary 
RGCs. To determine this, primary RGCs were transduced 
with either the AAV-2-GFP or AAV-2-ETA virus and sub-
sequently treated with ET-1 (100 nM) or ET-3 (100 nM). 
Cell viability was determined by treating for 30  min 
with the NUCLEAR-ID® Blue/Red cell viability reagent 
(Enzo Life Sciences). Cell death of RGCs transduced 
with AAV-2-GFP vector without endothelin treatment 
was 18.66  ±  0.03% (Fig.  7). Following 24  h treatment 
with 100 nM ET-1 or 100 nM ET-3, cell death of AAV-
2-GFP transduced RGCs was increased to 42.69 ±  0.11 
and 75.45 ± 0.10% (p < 0.0001), respectively. RGCs trans-
duced with the AAV-2-ETA vector showed significantly 
greater cell death, 53.86  ±  0.06% (p  <  0.05), compared 
to AAV-2-GFP transduced RGCs. Unlike AAV-2-GFP 
transduced RGCs, no exacerbation of cell death was 
observed in AAV-2-ETA transduced RGCs after 24  h 
treatment with either 100  nM ET-1 (60.57 ±  0.08%) or 
100 nM ET-3 (57.53 ± 0.03%). Similar to that observed in 
661W cells, total RGC numbers were decreased follow-
ing treatment with ET-1 or ET-3 and in RGCs transduced 
with AAV2-ETA.
ETA receptor overexpression increases ETB receptor 
expression in primary RGCs
Primary RGCs transduced with the AAV-2-ETA virus 
showed a 2.1 fold increase in ETA receptor expression 
(p < 0.001) compared to cell transduced with the AAV-2-
GFP virus (Fig. 8c). Immunostaining for the ETB receptor 
revealed a 4.4 fold increase in ETB receptor expression 
(p < 0.001) after transduction with AAV-2-ETA compared 
to AAV-2-GFP (Fig. 8d) .
Conclusions
The endothelin system has been established to have a 
neurodegenerative role in animal models of primary 
open angle glaucoma. Most of the focus in the literature 
has been on the ETB receptor, with previous studies from 
our lab demonstrating that the ETB receptor is a major 
contributor to glaucomatous neurodegeneration [21]. 
Although there has been very few studies focusing on the 
ETA receptor in glaucoma, some reports have alluded to a 
possible role for the ETA receptor in neurodegeneration.
Many reports indicate that one of the earliest site of 
damage during glaucoma is in the axons of RGCs at the 
optic nerve head suggestive of an axonopathy. Studies 
assessing axonal transport in the optic nerve following 
ET-1 administration found a decrease in the transport 
of mitochondrial subcomponents [24] and a disruption 
of the transport and delivery of fast axonal transport 
cargos [25]. At the optic nerve head ET-1 induces an 
increase in ETB receptors in optic nerve head astrocytes 
[26] and induces proliferation of astrocytes; however 
the proliferative antagonist was blocked using either 
an ETA or ETB antagonist [27] as well as the ETA/ETB 
Fig. 6 Overexpression of the ETA receptor can increase in ETB recep-
tor expression. a Representative images. Immunoblot showing the 
expression of ETA and ETB receptors in the plasma membrane fraction 
of 661W stable clones overexpressing the ETA receptor. b Immunob-
lot densitometry showing fold change in protein expression of both 
ETA and ETB receptors in 661W cells overexpressing the ETA receptor 
compared to empty vector cells. Protein normalized to calnexin 
expression. Bars represent mean ± SEM (n = 5). Asterisks indicated 
statistical significance *p < 0.05 by student’s t-test
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dual antagonist. These studies suggest that the endothe-
lin peptides have the ability to induce neurodegenera-
tive effects by numerous cellular mechanisms involving 
both ETA and ETB receptors. Howell et  al. [28] found 
an increase in mRNA expression of both ETA and ETB 
receptors at an early stage of disease progression in the 
DBA/2J mouse model of glaucoma. In addition, our lab 
has shown that ETA mRNA levels are also increased in 
the retina following IOP elevation in Brown Norway rats 
[29]. Furthermore, recent studies have shown significant 
neuroprotection using a dual endothelin antagonist [14, 
28]. These findings suggest that in addition to the ETB 
Fig. 7 ETA receptor overexpression increases cell death in primary RGCs. a Representative images of dead (red) and total (blue) RGCs following 
transduction with either AAV-2-GFP or AAV-2-ETA and 24 h treatment with 100 nM ET-1 or ET-3. Positive control shows RGCs treated with metha-
nol. b Quantitative analysis of percent cell death of RGCs. Bars represent mean ± SEM (n = 3). Asterisks indicated statistical significance *p < 0.05, 
****p < 0.0001 by one-way ANOVA and Tukey’s post hoc test
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receptor, the ETA receptor could also play a role in glau-
comatous neurodegeneration; however the precise role 
of the ETA receptor is largely unknown.
In this study we have demonstrated for the first time, 
by immunohistochemistry. that there is an increase 
in ETA receptor expression in multiple layers of the 
Fig. 8 Overexpression of the ETA receptor increases ETB receptor expression in primary RGCs. a, b Representative images. Immunostaining show-
ing the expression of ETA and ETB receptors in purified RGCs following transduction with either AAV-2-GFP or AAV-2-ETA. β-III-tubulin was used as 
a selective marker of RGCs. DAPI staining was used to visualize nuclei of RGCs. c, d Quantitative analysis of ETA receptor (c) and ETB receptor (d) 
expression in purified RGCs. Bars represent mean ± SEM (n = 3). Asterisks indicate statistical significance **p < 0.01 by student’s t-test
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retina following 2- and 4 weeks of IOP elevation, com-
pared to the corresponding contralateral control eyes in 
Brown Norway rats. We further demonstrated by mul-
tiple in  vitro techniques that ETA receptor overexpres-
sion leads to an overall decrease in cell viability of both 
661W cells and primary RGCs. The cell death observed 
in 661W cells was minimal, possibly due to confound-
ing effects of the cell line which is inherently prolifera-
tive, thereby attenuating the cell death inducing effect of 
endothelins. The ability of endothelins to promote cell 
death was clearly evident in the primary RGCs which do 
not proliferate since they are terminally differentiated. 
While ETA overexpression in primary RGCs produced 
increased cell death, there was no further exacerbation 
of cell death after treatment of these cells with ET-1 
and ET-3. This suggests that there was a threshold of 
endothelin receptor activation following ETA receptor 
overexpression, possibly due to autocrine effects medi-
ated by endothelin release from RGCs. In 661W cells 
stably overexpressing the ETA receptor, we observed a 
greater reduction in cell viability when treated with ET-3 
than when treated with ET-1 Considering that ET-3 is an 
ETB agonist which has low affinity for the ETA receptor, 
it was more likely that cell death was occurring due to 
ETA receptor mediated upregulation of the ETB recep-
tor. To support this conclusion we performed an immu-
noblot analysis of 661W cells stably overexpressing ETA 
receptors and found an increasing trend in ETB recep-
tors expression (not significant), compared to empty 
vector cells. In primary RGCs, immunostaining revealed 
AAV-2 mediated overexpression of the ETA receptor 
produced a greater than fourfold increase in ETB recep-
tor expression. In support of these findings, He et al. [30] 
showed that treatment of RGCs with either ET-1 or ET-3 
produced an increase in both ETA and ETB receptor pro-
teins detected by immunocytochemistry. Our findings, 
in this study and in conjunction with previous studies, 
have provided evidence that both ETA and ETB recep-
tors are upregulated due to an elevation in IOP in Brown 
Norway rats. It is generally accepted that the ETB recep-
tor is the major contributor to cell death of RGCs [21], 
however based upon our current findings, the involve-
ment of the ETA receptor in the upregulation of ETB 
receptors, thereby contributing to cell death, is a plausi-
ble scenario (Figs. 6, 8).
In animal models of traumatic brain injury an ETA 
receptor antagonist showed the ability to limit neuronal 
damage [31]. Pretreatment with BQ-123, an ETA recep-
tor antagonist significantly reduced axonal injury and 
improved retention of cognitive scores [32]. While the 
cellular and molecular mechanisms involved in neu-
roprotection in the brain and the retina might not be 
exactly the same, the greater neuroprotective effects of 
dual endothelin receptor antagonists, compared to ETB 
receptor selective inhibitors alone, suggests the involve-
ment of both receptors in neurodegeneration.
While it is evident that the endothelin receptors are 
upregulated during IOP elevation, some questions still 
need to be addressed in the future. One such ques-
tion is how does an increase in IOP lead to elevated 
endothelin levels and increased endothelin recep-
tor expression? The second question that still remains 
to be answered is what pathways are involved during 
endothelin receptor mediated neurodegeneration? 
One study showed that when shear stress is applied 
to endothelial cells there is an increase in ETB recep-
tors, c-jun, and AP-1 [33] and a study using a rodent 
model of glaucoma also showed involvement of AP-1 
and C/EBPβ in the upregulation of ETB receptors [29], 
although the mechanotransduction pathways have not 
been fully elucidated. Interestingly, following treatment 
of RGCs with either ET-1 or ET-3 we found an increase 
in both c-Jun and phospho-c-Jun suggesting that the 
JNK/c-Jun pathway may be a contributor to endothe-
lin receptor upregulation and endothelin-mediated 
cell death of RGCs. Assessment of the contribution of 
both endothelin receptors to glaucomatous neurode-
generation provides a good rationale for developing 
endothelin antagonists as neuroprotective agents for 
the treatment of glaucoma.
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